According to the results of the study, we found that the administration of the antiviral drug GS-5734 (remdesivir) and anti-inflammatory therapy reduces the level of TMPRSS2 in the blood, with the most significant changes observed in patients with moderate-severity COVID-19. The gene discussed is TMPRSS2; the disease is COVID-19.